ArticleScience translational medicine2017
Genomic profiling of ER
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 95 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 1 pooled it
10.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 1 synthesis or guideline pooled it, 122 citations in OpenAlex.
- Prognostic and Predictive Value ofFrontiers in endocrinology · 2022Pooled it
- Trial
- A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders.The Journal of clinical investigation · 2025Trial
- Genomic alterations are associated with response to aromatase inhibitor therapy for ER-positive postmenopausal ductal carcinoma in situ: (CALGB 40903, Alliance).Breast cancer research : BCR · 2025Trial
- A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HRClinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.Breast cancer research : BCR · 2019Trial
- Current Strategies and Emerging Paradigms of Immunotherapy in Microsatellite Stable Colorectal Cancer: A Review Article.Clinical drug investigation · 2026Review
- Baseline gene expression and dynamic endocrine therapy use in ER+ breast cancer: associations with recurrence in a real-world cohort.Research square · 2026Article
- ESR1 fusion proteins in breast cancer: distinguishing oncogenic drivers from passenger events.Oncogene · 2026Review
- CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer.The Journal of clinical investigation · 2026Article
- ESR1 fusions in breast cancer: functions, mechanisms and therapeutic opportunities.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- Article
- Patient derived xenograft models of hormone receptor positive and HER2 negative breast cancer from Indian patients.Scientific reports · 2025Article
- Genomic landscape of hormone therapy-resistant HR-positive, HER2-negative breast cancer.Breast cancer research and treatment · 2025Article
- Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations.Cancer letters · 2025Article
- Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies.Medical oncology (Northwood, London, England) · 2025Review
- Clinicopathological and molecular features of HRChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer.Nature reviews. Clinical oncology · 2024Review
- The role of vasculature and angiogenesis in respiratory diseases.Angiogenesis · 2024Review
35 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
35 authors at 10 institutions in 2 countries.
Jennifer M GiltnaneDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID http://orcid.org/0000-0002-8333-9995
Katherine E HutchinsonDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID http://orcid.org/0000-0002-4660-3523
Thomas P StrickerDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID http://orcid.org/0000-0002-3602-9994
Luigi FormisanoDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Christian D YoungDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Monica V EstradaBreast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID http://orcid.org/0000-0001-9846-8223
Mellissa J NixonDepartment of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.ORCID http://orcid.org/0000-0002-7749-5414
Liping DuVanderbilt Center for Quantitative Sciences, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.ORCID http://orcid.org/0000-0003-4926-2135
Violeta SanchezBreast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID http://orcid.org/0000-0001-6639-9024
Paula Gonzalez EricssonBreast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID http://orcid.org/0000-0002-6292-6963
Maria G KubaDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID http://orcid.org/0000-0003-0109-0231
Melinda E SandersDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID http://orcid.org/0000-0001-7227-1764
Xinmeng J MuBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID http://orcid.org/0000-0002-8079-0828
Eliezer M Van AllenBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID http://orcid.org/0000-0002-0201-4444
Nikhil WagleBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Ingrid A MayerBreast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID http://orcid.org/0000-0001-8147-335X
Vandana AbramsonBreast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Henry GόmezInstituto Nacional de Enfermedades Neoplásicas, Surquillo 15038, Peru.
Monica RizzoDepartment of Surgery, Emory University, Atlanta, GA 30322, USA.
Weiyi ToyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA.ORCID http://orcid.org/0000-0002-1369-123X
Sarat ChandarlapatyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA.ORCID http://orcid.org/0000-0003-4532-8053
Erica L MayerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID http://orcid.org/0000-0001-5430-8957
Jason ChristiansenGenoptix Medical Laboratories, Carlsbad, CA 92008, USA.ORCID http://orcid.org/0000-0001-9059-740X
Danielle MurphyGenoptix Medical Laboratories, Carlsbad, CA 92008, USA.ORCID http://orcid.org/0000-0003-1448-9444
Kerry FitzgeraldGenoptix Medical Laboratories, Carlsbad, CA 92008, USA.ORCID http://orcid.org/0000-0001-8104-255X
Kai WangFoundation Medicine Inc., Cambridge, MA 02141, USA.
Jeffrey S RossFoundation Medicine Inc., Cambridge, MA 02141, USA.ORCID http://orcid.org/0000-0001-8494-2596
Vincent A MillerFoundation Medicine Inc., Cambridge, MA 02141, USA.
Phillip J StephensFoundation Medicine Inc., Cambridge, MA 02141, USA.
Roman YelenskyFoundation Medicine Inc., Cambridge, MA 02141, USA.
Levi GarrawayBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Yu ShyrVanderbilt Center for Quantitative Sciences, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.ORCID http://orcid.org/0000-0003-2086-9670
Ingrid MeszoelyBreast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Justin M BalkoBreast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Carlos L ArteagaBreast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA. carlos.arteaga@vanderbilt.edu.ORCID http://orcid.org/0000-0003-0870-9586
Breast Cancer Research Foundation · USFoundation Medicine (United States)Broad Institute · USVanderbilt University Medical Center · USLineage Cell Therapeutics (United States) · USVanderbilt University · USMemorial Sloan Kettering Cancer Center · USDana-Farber Cancer Institute · USEmory University · USInstituto Nacional de Enfermedades Neoplásicas · PE
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8MTISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7MTherapeutic approaches to ER mutant breast cancerR01CA204999 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT · 2017 to 2021
$2.0MHigh-throughput Analysis of Mutations Identified by RNA-sequencing Triple NegativK08CA148912 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STRICKER, THOMAS PAUL · 2012 to 2016
$765kDusp4 in breast cancer: tumor suppressor biology and therapeutic strategiesR00CA181491 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BALKO, JUSTIN M · 2015 to 2017
$750kNCI NIH HHS K08 CA148912NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA068485NCI NIH HHS P50 CA098131NCI NIH HHS R00 CA181491NCI NIH HHS R01 CA204999
Abstract
Inhibition of proliferation in estrogen receptor-positive (ER
Indexed as
Breast NeoplasmsCell Line, TumorCyclin D1Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Erb-b2 Receptor Tyrosine KinasesFemaleHumansIn Vitro TechniquesReceptor, Fibroblast Growth Factor, Type 1Receptors, EstrogenCCND1 protein, humanCDK4 protein, humanCDK6 protein, humanCyclin D1Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFGFR1 protein, humanReceptor, Fibroblast Growth Factor, Type 1Receptors, Estrogen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.